FEMASYS INC
FEMY · Surgical & Medical Instruments & Apparatus · 60.4M shares · +119%/yr ↑ dilution · EDGAR filings ↗
Net buyback after stock comp: -$214K (gross $230K, SBC $444K)
Grade
D42Medical-device company (women's-health devices) with operating losses and cash burn.
Strengths
- Liquidity — current ratio 4.5 (68th)
Risks
- Operating/net losses & cash burn — per metrics
- micro-cap scale and commercialization risk — per 10-K
- Adoption/reimbursement dependence — per 10-K
Notable findings
- Going concern• There is substantial doubt about our ability to continue as a going concern
- Net lossNet loss (net margin -812.3%)
- Cash burnNegative free cash flow (-19.2M)
- Exec changeRecent 8-K item 5.02 8-K ↗
- Chronic dilutionShare count +119%/yr over 4y (dilution, book value/share -99%)
- FDA approvalFDA clearance/approval — FemVue® Controlled Saline-Air Device (FSA-300) (2025-12-15)
- Revenue declineRevenue -47.8% YoY
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
62.0%
Operating margin
-767.0%
Net margin
-812.3%
Return on equity
-317.4%
Return on assets
-89.9%
Revenue growth (QoQ)
-47.8%
Current ratio
4.5×
Free cash flow
-$19M
EBITDA
-$17M
Tangible book value
$6M
Cash & investments
$9M
Cash runway
2q
Stock comp / revenue
34.5%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-08-27 | Elefant Dov | I | 39K | — |
| 2025-08-27 | Lee-Sepsick Kathy | I | 49K | — |
| 2025-06-02 | Larsen Charles | I | 25K | $1.02 |
| 2025-06-02 | Currie Daniel Scott | I | 20K | $1.02 |
| 2025-06-02 | Elefant Dov | I | 20K | $1.02 |
| 2025-06-02 | Lee-Sepsick Kathy | I | 34K | $1.02 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05977751 ↗ | Prospective Multi-Center Trial for FemBloc Permanent Birth Control Contraception | NA | Recruiting | 2029-12-01 |
| NCT04273594 ↗ | FemBloc® Permanent Contraception - Confirmation Feasibility Trial Contraception | NA | Active Not Recruiting | 2022-09-30 |
| NCT04968847 ↗ | FemaSeed LOCAL Artificial Insemination Trial Infertility, Male Factor | NA | Completed | 2023-12-31 |
| NCT03433911 ↗ | FemBloc® Permanent Contraception - Early Pivotal Trial Contraception | NA | Completed | 2020-01-31 |
| NCT03067272 ↗ | Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception Contraception | NA | Completed | 2018-02-27 |
| NCT01053052 ↗ | Study of FemVue(TM) Sono Tubal Evaluation System Method Comparison to HSG Fallopian Tube Patency Tests | NA | Withdrawn | 2013-01-01 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-24 | 2026-06-24 | 0001140361-26-026239 ↗ |
| 8-K | 2026-06-24 | 2026-06-23 | 0001140361-26-026169 ↗ |
| 8-K | 2026-06-05 | 2026-06-05 | 0001140361-26-024265 ↗ |
| 8-K | 2026-06-04 | 2026-06-04 | 0001140361-26-023955 ↗ |
| 8-K | 2026-05-13 | 2026-05-13 | 0001140361-26-021081 ↗ |
| 10-Q | 2026-05-08 | 2026-03-31 | 0001140361-26-020115 ↗ |
| 8-K | 2026-05-08 | 2026-05-08 | 0001140361-26-020059 ↗ |
| 8-K | 2026-04-29 | 2026-04-29 | 0001140361-26-017805 ↗ |
| 8-K | 2026-04-01 | 2026-03-30 | 0001140361-26-012538 ↗ |
| 10-K | 2026-03-31 | 2025-12-31 | 0001140361-26-012375 ↗ |
| 8-K | 2026-03-31 | 2026-03-31 | 0001140361-26-012346 ↗ |
| 8-K | 2026-03-20 | 2026-03-17 | 0001140361-26-010591 ↗ |